Drugs / Alpha-0261
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07684560 | Jul 2026 → Mar 2027 expected | chronic idiopathic urticaria | AlphaMol Science Ltd. (Shanghai) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07279636 | Jul 2025 → Feb 2026 | — | AlphaMol Science Ltd. (Shanghai) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-0261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07279636 ↗ |
| Route | Oral | “Oral, tablet” NCT07279636 ↗ |